Exercise the right to try oleandrin

On Friday, President Trump tweeted that the Deep State at the Food and Drug Administration has been slow-rolling promising treatments for the Chinese Communist Party virus for political reasons.

By Sunday, he was able to announce that the FDA had cleared one called “convalescent plasma” for emergency use. Good news! Better yet, the President secured the agreement of the FDA’s Commissioner that – if a treatment is safe and effective – those afflicted with the CCP virus have a “Right to Try” it.

Dr. Stephen Hahn’s agency knows that the safety and effectiveness of an even-more-promising treatment called oleandrin has been established to the point where it should be made available for widespread, lifesaving human trials and sold as a natural supplement.

We have a right to try oleandrin and the FDA must clear the way for us to do so. Now.

This is Frank Gaffney.

About Frank Gaffney, Jr.

Frank Gaffney is the Founder and Executive Chairman of the Center for Security Policy in Washington, D.C. Under Mr. Gaffney's leadership, the Center has been nationally and internationally recognized as a resource for timely, informed and penetrating analyses of foreign and defense policy matters. Mr. Gaffney formerly acted as the Assistant Secretary of Defense for International Security Policy during the Reagan Administration, following four years of service as the Deputy Assistant Secretary of Defense for Nuclear Forces and Arms Control Policy. Previously, he was a professional staff member on the Senate Armed Services Committee under the chairmanship of the late Senator John Tower, and a national security legislative aide to the late Senator Henry M. Jackson.